Boston Scientific Corporation
HealthcareNYSE:BSX · New York Stock Exchange
-$0.23 today
Vol 9.43M · Avg 18.98M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
11.9%
avg 8.6%
ROIC
8.8%
avg 5.5%
ROA
6.6%
avg 4.1%
Analysis
ROE is currently the strongest return metric at 11.9% versus its period average of 8.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael F. Mahoney | Chairman, President & Chief Executive Officer | $5.73M | — | 61 | $0.00 | <0.01% |
Joseph Fitzgerald | Executive VP & Group President of Cardiovascular | $2.40M | — | 62 | $213,907.00 | 0.01% |
Arthur Crosswell Butcher | Executive Vice President and Group President of MedSurg & Asia Pacific | $1.98M | — | 55 | $57,894.00 | <0.01% |
Vance R. Brown | EVP, General Counsel & Corporate Secretary | $1.60M | — | 56 | $0.00 | <0.01% |
Jonathan Monson | Executive Vice President & Chief Financial Officer | $1.47M | — | 52 | $38,426.00 | <0.01% |
Adam Smith | General Manager of Global Sales & Marketing | — | — | — | $4,679.00 | <0.01% |
Paudie O'Connor | Executive Vice President of Global Operations | — | — | 58 | $7,024.00 | <0.01% |
Brenda Becker | Senior Vice President of Global Government Affairs | — | — | 66 | — | — |
Emily Woodworth | Senior Vice President, Global Controller & Chief Accounting Officer | — | — | 48 | $3,231.00 | <0.01% |
Miriam O'sullivan | Senior Vice President & Chief Human Resources Officer | — | — | 45 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$553,999.79
Sells
12
$31.56M
Net Sentiment
$31.01M
Net selling
Most Active
Fitzgerald Joseph Michael
6 transactions
1–10 of 16
Analysis
Insiders reported 4 buys worth $553,999.79 and 12 sells worth $31.56M over the last 12 months. That adds up to net selling of $31.01M. Fitzgerald Joseph Michael was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +1.0% | +9.8% (15yr)12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | -7.4% | +12.4% (15yr)12 analysts |
Analysis
Recent growth has been strongest in Revenue at +1.0% over three years. Forward estimates point to EBIT at +12.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$190.57B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.42B
Abbott Laboratories
NYSE:ABT
$152.37B
Pfizer Inc.
NYSE:PFE
$149.13B
Danaher Corporation
NYSE:DHR
$127.49B
Stryker Corporation
NYSE:SYK
$119.98B
Sanofi
NASDAQ:SNY
$106.49B
Medtronic plc
NYSE:MDT
$102.95B
McKesson Corporation
NYSE:MCK
$94.97B
HCA Healthcare, Inc.
NYSE:HCA
$85.93B
Who manages BSX?
Boston Scientific Corporation (BSX) lists 10 active executives. The top listed executive is Adam Smith, General Manager of Global Sales & Marketing.
Are BSX insiders buying or selling?
Recent insider activity shows net selling of $26.40M.
Explore More
Continue the stock analysis
Jump to another research area for this company.